Abstract
In recent years, immunotherapy has become an integral part of the treatment of bronchogenic carcinoma and in 2015 it was approved for advanced treatment of advanced non-small cell lung cancer (NSCLC). It is currently the standard of treatment not only in this indication (nivolumab, pembrolizumab, atezolizumab), but also in stage III after chemoradiation treatment (durvalumab) and in the first line treatment of metastatic NSCLC.
We now have the results of a study in extensive small cell carcinoma lung (ES-SCLC), for which no progress has been made for several decades. In September 2019, atezolizumab was approved as the first checkpoint inhibitor in combination with first-line chemotherapy for this disease.